

Severe Acute Respiratory Syndrome Corona Virus 2-like particles (Ha-CoV-2), Omicron (B.1.1.529) Catalog #: 0568-PP-020

Description:

The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (Luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirus-based vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle.

Formulation & Storage: Available upon request
Store at -80°C.

Notes & Usage Guidelines:

Spike Mutations: Spike A67V, Spike H69del, Spike V70del, Spike T95I, Spike G142D, Spike V143del, Spike Y144del, Spike Y145del, Spike N211del, Spike L212I, Spike ins214EPE, Spike G339D, Spike S371L, Spike S373P, Spike S375F, Spike K417N, Spike N440K, Spike G446S, Spike S477N, Spike T478K, Spike E484A, Spike Q493R, Spike G496S, Spike Q498R, Spike N501Y, Spike Y505H, Spike T547K, Spike D614G, Spike H655Y, Spike N679K, Spike P681H, Spike N764K, Spike D796Y, Spike N856K, Spike Q954H, Spike N969K, Spike L981F

Size: 25 X 200 µL ~100 wells/96 well plate or 60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP

Applications


- Screening and quantification of anti-coronavirus-neutralizing antibodies
- Anti-coronavirus drug screening
- Quantification of viral mutants' infectivity
- Identification of host co-factors and restriction factors of coronaviruses

Hybrid alpha-Pseudovirus Neutralization Assay Protocol:

A monolayer of Vero cells is infected with VLPs or a mixture of VLPs and test sample for approximately 1 hr in a dilution block. Cells are overlaid with 1-2% FBS supplemented media and incubated overnight at 37°C + 5% CO₂. Following overnight incubation, luciferase activity is measured by adding an appropriate substrate like Bright-Glo™ or Luciferase Assay System (Promega). Plates can be read immediately on an instrument such as BioTek Cytation™ or similar. Relative neutralization activity is measured by comparing treated versus untreated wells (or virus only control). In dose response experiments the concentration of TA resulting in 50% neutralization (IC₅₀) is determined.

Repeated freeze/thaw cycles are not recommended as it may affect viral titer and infectivity.

Left: Comparison of Ha-CoV-2 with S protein pseudotyped lentivirus in a time course of infection and reporter expression



Certificate of analysis:

A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information. For older lots, refer to the applicable certificate of analysis that may be requested at services@ibtbioservices.com

Related Products:

IBT provides a wide array of anti-filovirus specific antibodies, recombinant proteins, and other infectious disease reagents. Please see our website, www.ibtbioservices.com for more details.

Intended for research use only, not for human, therapeutic, or diagnostic applications.

The buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of Integrated BioTherapeutics, LLC.

Copyright 2023. Integrated BioTherapeutics, LLC. All rights reserved.